Skip to search.
 TSX Up0.40% TSX Ventures Down1.68%

More On I.TO

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


IntelliPharmaCeutics International Inc (I.TO)

-Toronto
2.09 Down 0.01(0.48%) 3:59PM EDT
ProfileGet Profile for:
IntelliPharmaCeutics International Inc
30 Worcester Road
Toronto, ON M9W 5X2
Canada - Map
Phone: 416-798-3001
Fax: 416-798-3007
Website: http://www.intellipharmaceutics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. The company also develops Rexista Oxycodone XR, an abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain; Regabatin XR, a pregabalin extended-release capsule use for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration that contains venlafaxine hydrochloride; Protonix, a delayed-release capsule for oral administration that contains pantoprazole sodium; and Glucophage, an oral antihyperglycemia drug used in the management of type 2 diabetes. In addition, its products include Seroquel XR, an oral psychotropic agent use for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug used in the treatment of epilepsy; Keppra XR, an antiepileptic drug indicated for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, an inhibitor use for the treatment of major depressive disorder. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical, Inc. The company was founded in 1998 and is based in Toronto, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on IntelliPharmaCeutics International Inc

Key Executives 
 PayExercised
Dr. Isa Odidi Ph.D., MBA, 58
Co-Founder, Chairman, Chief Exec. Officer and Chairman of the Scientific Advisory Board
373.00k0.00
Dr. Amina Odidi Ph.D., 56
Pres, Chief Operating Officer, Co-Chief Scientific Officer and Director
373.00k0.00
Mr. Domenic Della Penna ,
Chief Financial Officer
232.00k0.00
Mr. John Newell Allport B.A.Sc., M.A., LL.B., 70
VP of Legal Affairs & Licensing, Sec., Director and Member of Corp. Governance Committee
129.00k0.00
Dr. Patrick N. Yat Ph.D., 58
VP of Pharmaceutical Analysis & Chemistry
N/AN/A
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.